Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHIT1 | Q13231 | 3/20 | 0.43 |
| ▸ | CHIA | Q9BZP6 | 3/20 | 0.43 |
| ▸ | FPR2 | P25090 | 4/20 | 0.43 |
| ▸ | PROKR1 | Q8TCW9 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18577265 | 1.00 | CHIT1 (0.43) | CHIT1CHIAFPR2PROKR1MEN1 | |
| Hydrochloric Acid SCHEMBL31302250 | 0.85 | CA1 (0.50) | POLBKMT2AL3MBTL1CA1CA2 | |
| Hydrochloric Acid SCHEMBL6936614 | 0.85 | CA1 (0.50) | POLBKMT2AL3MBTL1CA1CA2 | |
| Trifluoroacetic Acid SCHEMBL31302273 | 0.78 | CA1 (0.49) | POLBKMT2AL3MBTL1CA1CA2 | |
| Trifluoroacetic Acid SCHEMBL30259772 | 0.78 | CA1 (0.49) | POLBKMT2AL3MBTL1CA1CA2 | |
| SCHEMBL18577325 | 0.77 | CMA1 (0.44) | CHIT1CHIAFPR2PROKR1MEN1 | |
| SCHEMBL18586831 | 0.77 | CMA1 (0.44) | CHIT1CHIAFPR2PROKR1MEN1 | |
| SCHEMBL18610265 | 0.77 | KMT2A (0.41) | CHIT1CHIAFPR2PROKR1MEN1 | |
| SCHEMBL18610270 | 0.75 | ALDH1A1 (0.35) | FPR2PROKR1POLBCA1CA2 | |
| SCHEMBL18577366 | 0.75 | CHIT1 (0.45) | CHIT1CHIAFPR2PROKR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190345137-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | GALAPAGOS NV (BE) | 2019-11-14 | — | — | US | disclosed |
| US-20190345137-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | GALAPAGOS NV (BE) | 2019-11-14 | — | — | US | disclosed |
| US-10208020-B2 | Substituted amino triazoles useful as human chitinase inhibitors | Oncoarendi Therapeutics S.A. (PL) | 2019-02-19 | — | — | US | disclosed |
| EP-3344616-B1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | ONCOARENDI THERAPEUTICS SA (PL) | 2019-01-09 | — | — | EP | disclosed |
| US-20180258071-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | GALAPAGOS NV (BE) | 2018-09-13 | — | — | US | disclosed |
| US-9944624-B2 | Substituted amino triazoles useful as human chitinase inhibitors | Oncoarendi Therapeutics S.A. (PL) | 2018-04-17 | — | — | US | disclosed |
| US-9944624-B2 | Substituted amino triazoles useful as human chitinase inhibitors | Oncoarendi Therapeutics S.A. (PL) | 2018-04-17 | — | — | US | disclosed |
| US-9944624-B2 | Substituted amino triazoles useful as human chitinase inhibitors | Oncoarendi Therapeutics S.A. (PL) | 2018-04-17 | — | — | US | disclosed |
| US-20170066743-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | GALAPAGOS NV (BE) | 2017-03-09 | — | — | US | disclosed |
| US-20170066743-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | GALAPAGOS NV (BE) | 2017-03-09 | — | — | US | disclosed |
| US-20170066743-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | GALAPAGOS NV (BE) | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345137-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | CHIA, CHIT1, AADAC | CHIT1 2/4885CHIA 1/4885FPR2 1217/4885 |
| US-10208020-B2 | Substituted amino triazoles useful as human chitinase inhibitors | CHIA, CHIT1, AADAC | CHIT1 2/4885CHIA 1/4885FPR2 1217/4885 |
| US-20170066743-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | CHIA, CHIT1, AADAC | CHIT1 2/4885CHIA 1/4885FPR2 1217/4885 |
| US-20180258071-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | CHIA, CHIT1, AADAC | CHIT1 2/4885CHIA 1/4885FPR2 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.